Novartis Pharma

Novartis Pharma is a leading pharmaceutical company that owns a portfolio of prescription drugs leading in modern pharmacology. More than 40 names of leading drugs have been developed and presented on the market by Novartis. These are drugs for the treatment of diseases in the fields of oncology, transplantology, cardiology, ophthalmology, psychiatry, dermatology and allergic diseases of the respiratory tract.

Business in Russia

In Russia, the Novartis Pharma division has existed since 1996. As of May 2012, the number of employees throughout the country is about 800 people.

The administrative offices of the division are located in, To Moscow,, St. Petersburg,, and Yekaterinburg. Novosibirsk Kazan Rostov-on-Don

As a leader among foreign manufacturers in clinical research in Russia, Novartis Pharma cooperates with the Russian scientific medical community and supports the development of key therapeutic areas in medical science and practice:

• cardiology,
• rheumatology,
• endocrinology,
• oncology,
• neurology,
• ophthalmology,
• transplantology,
• respiratory and infectious diseases.

2024: Ivan Polyak's appointment as CEO of the division

Ivan Polyak headed the Russian division of Novartis. This became known in January 2024, but Polyak became the general director of Novartis Pharma LLC on November 1, 2023, the company said. Read more here.

Performance indicators

2024: 7th place in revenue among global pharmaceutical companies - $50.3 billion

The American corporation Merck topped the rating of the world's largest pharmaceutical companies at the end of fiscal 2024 with revenue of $64.2 billion, maintaining its leading position for the second year in a row thanks to sales of the anticancer drug Keytruda for $29.5 billion. The top ten pharmaceutical manufacturers by revenue include both traditional American giants and European companies, demonstrating steady growth in the context of the changing competitive environment of the industry. The rating was compiled by the experts of the publication in September 2025. Read more here

2020: Global Cancer Drugs Market Share - 6.6%

Novartis' share of the global cancer drug market was 6.6% (Evaluate data). Read more here.

2018: Volume of drug imports to Russia

In 2018, Novartis showed the maximum volume of drug imports to Russia compared to other foreign suppliers. The company imported products worth 41.6 billion rubles. (taking into account the cost of customs clearance and VAT). Read more here.

Notes